Navigation Links
Infinata’s BioPharm Insight to Offer Exclusive Preview of 2013 Key Reports at the BIO International Conference and Partnerships in Clinical Trials
Date:4/19/2013

Norwood, MA (PRWEB) April 19, 2013

BioPharm Insight(TM), Infinata’s flagship intelligence solution for the global biopharmaceutical community, will be active participants the upcoming BIO International Conference and the 22nd Annual Partnerships in Clinical Trials conference this month, with an exclusive preview of key reports for 2013:

May Catalyst Monitor highlights significant upcoming catalysts, including:

  • Difficulties AVEO’s tivozanib might face if approved for advanced renal cell carcinoma
  • Whether Delcath’s Melblez progression-free survival data is sufficient enough for US approval
  • Nektar Therapeutic’s NKTR-118 in opioid-induced constipation

CRO/CMO Quarterly Report analyzes clinical study activity across the globe. Included within the report is clinical activity by region and country, therapeutic area, and site activity. One trend reported was a drop in the number of clinical trials and the number of enrolled patients in the first quarter of 2013 compared to the first quarter of 2012.

Orphan Drugs Report discusses the top global trends within the orphan disease space, including forward-looking editorial coverage on:

  • Amicus’ and BioMarin’s drug candidates for Pompe disease
  • Xenikos co-development discussions for orphan GVHD drug
  • Case-by-case reimbursement for Aegerion’s Juxtapid and Sanofi/Isis’ Kynamro

Post-ACC Report summarizing our editorial team’s coverage of the American College of Cardiology Meeting. Significant industry topics include:

  • Portola’s betrixaban faces comparison to past failures and possibility for safety issues in ongoing Phase III APEX study
  • Experts views on Bayer and J&J’s plans to pursue anticoagulant Xarelto in coronary artery disease and chronic heart failure
  • Merck’s vorapaxar approval chances in myocardial infarction

To learn how BioPharm Insight can help you find new business opportunities, stop by booth #210 at Partnerships in Clinical Trials for an onsite demo or start your free trial today. Gain access to all the data, analytics and intelligence mentioned in this news release.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com. Follow BioPharm Insight on LinkedIn and Twitter.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10649225.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
2. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
3. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
4. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
5. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
6. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
7. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
8. Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
9. BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
10. BioPharm Insight Releases its Catalyst Monitor for April 2013
11. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic ... Symposium. Using molecular test results from tumors with previously documented positive, negative, ...
(Date:12/2/2016)... ... December 01, 2016 , ... PhUSE will build ... popularity of US Single Day Events (SDE) to organize a multiple-day US conference. ... Raleigh, NC. Topics of the pharmaceutical and life sciences industry will cover industry ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only ... a beautiful technology experience. All three tenets were on display at the 2nd Annual ... from over 40 sponsor, CRO and site organizations to discuss innovation and the future ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved chemistry, ... in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
Breaking Biology Technology:
(Date:11/22/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the company has been ... Awards as "Most Outstanding in eClinical Solutions" for ... recognition and growth for MedNet, which has effectively supported ... iMedNet ™ , MedNet,s flagship eClinical technology ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):